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The mouse adenocarcinoma of the colon (MAC)
series of transplantable tumours (Double et al.,
1975) has been used in a variety of chemotherapy
studies. They have many characteristics in common
with human large bowel cancer (Ball & Double,
1975; Double & Ball, 1975) and they are easy to
maintain in serial passage. The rationale behind
their development was the provision of a
range of transplantable lines showing a spectrum of
histology and chemosensitivity similar to that seen
in the clinic. In man the histological appearance of
colon carcinomas varies considerably with most
being well-or moderately-differentiated tubular
adenocarcinomas and only about 20% being poorly
differentiated or anaplastic. Much of the previous
work with the MAC tumours has concentrated on
the moderately-differentiated lines (Double &
Carter, 1978; Double & Cifuentes de Castro, 1978;
Bibby et al., 1981). In the present investigation we
present chemotherapy screening data from a mucin
producing tumour (MAC 30T). This expands our
panel of MAC tumours to include lines with
different growth rates and with histology ranging
from anaplastic to well-differentiated.
Pure-strain female NMRI mice (age 6-8 weeks)
from our inbred colony were used. Animals were
fed diet 86 (James Burnhill & Sons, Cleckheaton,
England) and water ad libitum. The development of
several transplantable adenocarcinomas of the large
bowel from primary tumours induced by prolonged
administration of 1,2-dimethyl hydrazine has been
described elsewhere (Double et al., 1975).
MAC 30T (previously designated MAC 30) was
first briefly described by Cowen et al. (1980) but
has subsequently been serially passaged for a period
of 39 months. Tumours were transplanted into
normal mice by s.c. implantation of tumour
fragements in the flank. The tumour was excised
from donor animals and placed in TC 199 medium
(Wellcome Reagents Ltd., U.K.) containing
streptomycin (2980 uml -1) and penicillin
(400pml-1) and cut into small fragments
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-1 x 2mm in size. Fragments were implanted into
the flank using a trocar. Positive takes can only be
identified 2-3 weeks after transplantation.
All histological specimens were fixed in 10%
buffered formalin and sections were stained with
haematoxylin and eosin, periodic acid Schiff (PAS)
or Alcian Blue (AB).
Fourteen days after transplantation (the shortest
time at which accurate measurements could be
made) tumour-bearing mice were allocated into
groups of 8 by restricted randomisation. (These
tumours exhibit a take rate of almost 100%).
Chemotherapy commenced on Day 0 and its effects
were assessed by serial, twice weekly, two-
dimensional caliper measurements. Tumour volume
was calculated from the formula a2 x b/2 where a is
the smaller diameter and b is the larger (Geran et
al., 1972). Tumour volumes were normalised with
respect to their starting volumes and semi-log plots
were drawn of relative tumour volume (RTV)
against time. Slopes of the growth curves were
calculated and the best lines of fit were drawn. The
control plot was constructed from data pooled from
the whole series of experiments. In the treated
group the best lines of fit were drawn on the graph
from the points after treatment where exponential
regrowth commenced. Fractional volume reduction
and specific growth delay were also calculated for
each drug at maximum tolerated dose as Steel et
al., (1983), suggest that only these methods permit
comparison between different tumour lines.
All injections were i.p. Aclacinomycin A and
Adriamycin (supplied by Lundbeck Ltd., U.K.)
cyclophosphamide (supplied by Ward Blenkinsop,
U.K.), 5 fluorouracil (FU) (supplied by Roche,
U.K.) and vindesine (supplied by Eli Lilly, U.K.)
were dissolved in isotonic saline. 1-(2-chloro-
ethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-
CCNU) (supplied by Dr J.M. Venditti, NCI,
U.S.A.) was dissolved in 10% ethanol/arachis oil.
Dacarbazine (DTIC) (supplied by NCI) was
suspended in arachis oil. Treosulfan (supplied by
Leo Laboratories, U.K.) was dissolved in DMSO
and CB 1954 (supplied by Dr D.E.V. Wilman,
Chester Beatty Research Institute) was dissolved in
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10% DMSO/arachis oil. In all cases except for
Treosulfan the drugs were dissolved at an
appropriate concentration for a desired dose to be
administered in 0.1 ml per lOg body weight.
Treosulfan was dissolved to give the appropriate
dosage in 0.2ml DMSO.
MAC 30T is a well-differentiated mucoid tubular
adenocarcinoma which has remained histologically
unaltered for 39 months. The epithelium of the
tubules contains goblet cells with PAS and AB
positive contents. The growth rate of the untreated
tumours has remained consistant throughout the
course of these experiments with a mean volume
doubling time of 4 days (Figure 1). Distant
metastases have not been observed with this
tumour line but skin invasion with ulceration does
sometimes occur as does local muscle invasion.
The anti-tumour activity of a series of standard
agents was determined by assessing growth delay at
a RTV of 5 (Table I). Like other tumour lines
within the MAC series responses are only seen close
to maximum tolerated dose (MTD). The results
indicate that the best responses are seen with the
alkylating agents methyl-CCNU (Figure 2) and
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Figure 1 MAC 30/T control growth curve.
Table I Response of MAC 30T to a series of anti-tumour agents
Dose Growth Specific Fractional
level Delay growth volume
Agent (mgkg- )t Survivors (days) delay reduction
Aclacinomycin 10 8/8 NS
20 8/8 4.5* 0.52 0.37
40 0/8
Adriamycin 8 8/8 NS
12 7/8 NS
18 2/8
CB 1954 100 8/8 NS
Cyclophosphamide 300 8/8 12* 1.37 0.95
400 5/8 17 -
DTIC 150 8/8 1.6
300 8/8 6.2* 0.72 0.60
400 7/8 6.2 -
FU 120 8/8 3.4* 0.40 0.22
180 4/8 NS
MeCCNU 30 8/8 17.8* 2.18 1.35
40 7/8 32 (at RTV2)
Treosulfan 2gkg-1 8/8 NS
3gkg-1 8/8 10* 1.16 0.61
4gkg-1 5/8 3.1 -
Vindesine 2 8/8 NS*
3 7/8 NS
NS Nosignificant growth delay
*Approximate maximum tolerated dose.
- Not calculated
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Figure 2 Effects of methyl CCNU on the growth of
MAC 30/T ([1 30mgkg-l, * 40mgkg- -, control).
cyclophosphamide. At a dose level of 30mgkg-1
methyl-CCNU produced a growth delay of 17.8
days. A dose of 40mgkg-1 methyl-CCNU
produced a growth delay of 32 days at the expense
of host toxicity. This group of animals had failed to
reach RTV 5 by Day 39 when the experiment was
terminated. Cyclophosphamide at MTD gives a
growth delay of 12 days and Treosulfan, a
bifunctional alkylating agent produces a growth
delay of 10 days at MTD (Figure 3). The
antimetabolite FU at MTD produced a delay of
only 3.4 days. DTIC at MTD gives a growth delay
of 6.2 days. The tumour did not respond to
Adriamycin but a growth delay of 4.5 days was
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Figure 3 Effects of Treosulfan on
MAC 30/T (O> 2gkg-', * 3gkg-, -
seen with Aclacinomycin A at a dose level of
20mgkg-1. If anti-tumour effect is measured as
specific growth delay or fractional volume
reduction instead of growth delay a similar picture
is obtained (Table I).
The object of this study was to characterise a
relatively new transplantable mouse colon tumour
line with a histological appearance that widens the
range of tumours within the MAC tumour panel.
The chemosensitivity of MAC 30T appears to be
broadly similar to that shown by the less well
differentiated lines of the MAC series. In general
useful responses are only seen close to maximum
tolerated dose and best responses are again seen
with the nitrosoureas and cyclophosphamide. There
are, however, some subtle differences in its response
to standard agents that may be worthy of further
investigation. For example, it is, only poorly
responsive to FU when compared with all other
MAC lines, it is more responsive to Treosulfan
than another well differentiated line MAC 26 and
the observation that tumour regrowth following
Treosulfan does not parallel that of the controls
may indicate some unusual mechanism of action on
this line which may be of interest. Similarly it is
unresponsive to Adriamycin but responds to a new
anthracycline derivative Aclacinomycin A and this
may be of value in mechanistic studies.
The results have also been presented as specific
growth delay and fractional volume reduction. This
does not alter the ranking of compounds in order
of anti-tumour activity as one is calculated from
the other but as Steel et al. (1983) point out these
methods permit comparison of activity to be made
between systems with differing growth rates. It will
be adopted in our future studies on tumour systems
where growth can be realistically followed.
It is debatable (Cowen et al., 1982) whether
murine transplantable tumours or transplantable
tumour lines of any other species of laboratory
animals can be a model for human cancer or
whether it is necessary to use tumours from a
similar tissue of origin to that of the human
tumour. In the meantime, chemotherapeutic drugs
will still need initial screening and evaluation in
animal models and it is considered that the
enlarged MAC series would be eminently suited to
such programes, particularly as it is likely that
tumour architecture may influence
pharmacokinetics, drug disposition and
bioavailability at the cellular level.
We wish to thank Mrs A.R. Tilley for enthusiastic and
20 25 skilful technical help and Mr. A.M. Scholley for providing
computer programmes and valuable help with the
statistical analysis.
the growth of This work was supported by the Whyte Watson/Turner
- control). Cancer Research Trust, Bradford.
741742 J.A. DOUBLE et al.
References
BALL, C.R. & DOUBLE, J.A. (1975). Transplantable colon
tumours as chemotherapy screening models. Cancer,
36, 2437.
BIBBY, M.C., DOUBLE, J.A. & MUGHAL, M.A. (1981).
Effects of nandrolone decanoate on the toxicity and
anti tumour action of CCNU and FU in murine
tumours. Br. J. Cancer, 44, 572.
COWEN, D.M., DOUBLE, J.A. & COWEN, P.N. (1980). Some
biological characteristics of transplantable lines of
mouse adenocarcinomas of the colon. J. Natl Cancer
Inst., 64, 675.
COWEN, D.M., SIEGERSTETTER, J., JANIK, A.C. &
DOUBLE, J.A. (1982). An assessment of response of
murine transplantable colon tumours to combination
chemotherapy. J. Cancer Res. Clin. Oncol., 103, 119.
DOUBLE, J.A. & BALL, C.R. (1975). Chemotherapy of
transplantable colon tumours in mice. Cancer
Chemother. Rep., 59, 1083.
DOUBLE, J.A., BALL, C.R. & COWEN, P.M. (1975).
Transplantation of adenocarcinomas of the colon in
mice. J. Natl Cancer Inst., 54, 271.
DOUBLE, J.A. & CARTER, M.E. (1978). The
characterisation of a mouse model system for
colorectal cancer and its response to 5-fluorouracil.
Eur. J. Cancer, (Suppl. 1.) 105.
DOUBLE, J.A. & CIFUENTES DE CASTRO, L. (1978).
Chemotherapy of transplantable adenocarcinomas of
the colon in mice. II Development and characterisation
of an ascitic line. Cancer Treat. Rep., 62, 85.
GERAN, R.I., GREENBERG, N.H., MACDONALD, M.M.
SCHUMACHER, A.M. & ABBOT, B.J. (1972). Protocols
for screening chemical agents and natural products
against animal tumours and other biological systems
(30 edn). Cancer Chemother. Rep. (Pt. 3), 2, 1.
STEEL, G.G., COURTENAY, V.D. & PECKHAM, M.J.
(1983). The response to chemotherapy of a variety of
human tumour xenografts. Br. J. Cancer, 47, 1.